ArticleOphthalmic plastic and reconstructive surgery
Multidisciplinary management of lacrimal sac/nasolacrimal duct carcinomas.
Article in Ophthalmic plastic and reconstructive surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 70 citations in OpenAlex.
- Review
- Primary adenocarcinoma of the lacrimal sac with 5-year recurrence-free survival after radiation therapy alone: a case report.International cancer conference journal · 2025Article
- Nasolacrimal Metastasis from Parotid Ductal Carcinoma Detected byMolecular imaging and radionuclide therapy · 2025Article
- Neoadjuvant Chemotherapy Alone or Combined with EGFR-Directed Targeted Therapy or Anti-PD-1 Immunotherapy for Locally Advanced Lacrimal Sac and Nasolacrimal Duct Carcinomas.Seminars in ophthalmology · 2024Article
- Difficulties of nasocutaneous fistula repair, following lacrimal outflow system malignancy resection.Orbit (Amsterdam, Netherlands) · 2024Article
- Poorly differentiated sebaceous carcinoma of the lacrimal sac in a young adult: A case report.SAGE open medical case reports · 2024Article
- Lacrimal sac squamous cell carcinoma: From resection to prosthetic rehabilitation. A case report.Clinical case reports · 2023Article
- Value ofDiagnostics (Basel, Switzerland) · 2021Article
- Rare transitional cell carcinoma of the lacrimal sac.American journal of ophthalmology case reports · 2020Article
- Treatment outcomes after definitive radio(chemo)therapy for 17 lacrimal sac squamous cell carcinoma.The British journal of radiology · 2020Review
- Complete resolution of a large squamous cell carcinoma of the lacrimal duct in a young African American male after non-surgical management.American journal of ophthalmology case reports · 2020Article
- Mucoepidermoid Carcinoma of the Lacrimal Sac: Clinical-Pathologic Analysis, Including Molecular Genetics.Ocular oncology and pathology · 2020Article
- Lacrimal Sac Metastasis from Phyllodes Tumor of the Breast.Korean journal of ophthalmology : KJO · 2020Article
- Comparison of Clinical Features and Treatment Outcome in Benign and Malignant Lacrimal Sac Tumors.BioMed research international · 2020Article
- Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer.Oral oncology · 2019Review
- Clinical analysis of 90 cases of malignant lacrimal sac tumor.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2018Article
- Review
- Androgen receptor-positive ductal adenocarcinoma of the nasolacrimal duct: A case report.American journal of ophthalmology case reports · 2017Article
- Imaging Features of Malignant Lacrimal Sac and Nasolacrimal Duct Tumors.AJNR. American journal of neuroradiology · 2016Article
- Surgical resection of invasive adenoid cystic carcinoma of the lacrimal gland and wound closure using a vertical rectus abdominis myocutaneous free flap.BMJ case reports · 2016Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo determine the rates of globe-sparing treatment and useful final visual function in patients with primary lacrimal sac/nasolacrimal duct carcinomas treated with multidisciplinary therapy.
methodsThe medical records of 14 patients with primary lacrimal sac/nasolacrimal duct carcinoma treated at 1 institution were retrospectively reviewed.
resultsThe patients were 9 men and 5 women; the median age at diagnosis was 58.5 years (range, 45-73 years). Seven patients presented with epiphora, 7 with a palpable mass in the inferomedial orbit, and 2 with dacryocystitis. In 3 patients, the diagnosis of cancer was not considered until during or after dacryocystorhinostomy. Seven patients had squamous cell carcinoma, 2 transitional cell carcinoma, 2 adenoid cystic carcinoma, and 1 each adenocarcinoma, poorly differentiated carcinoma, and inverted papilloma with carcinoma in situ transformation. Nine patients underwent surgical resection of the lacrimal sac and nasolacrimal duct and resection of the medial upper and lower eyelids, including canaliculi, partial ethmoidectomy, and medial maxillectomy. One patient underwent lacrimal sac biopsy only as another primary malignancy was discovered during the work-up for systemic disease. Four patients underwent orbital exenteration because of extensive involvement of the orbital soft tissue. Radiotherapy was recommended for 13 patients; in 1 patient, radiotherapy was not recommended because the patient had an inverted papilloma with carcinoma in situ transformation that was completely excised. The median radiation dose was 60 Gy. Eight patients received chemotherapy either concurrent with radiation therapy (5 patients), as neoadjuvant treatment (1 patient), or for progressive or metastatic disease (3 patients). The median follow-up time was 27 months (range, 6-96 months). In 10 patients, the globe was spared. In 9 of these 10 patients, visual acuity was the same as at baseline or better than 20/40 at last follow up.
conclusionsWith multidisciplinary therapy, the eye can be spared and reasonable visual function can be preserved in most patients with primary lacrimal sac/nasolacrimal duct carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.